Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
IT0004147952
Tue, 04.05.2021
Newron Pharmaceuticals SpA
Milan, Italy - May 4, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it received a Paragraph IV Notice Letter regarding the submission by a generic manufact [ … ]
Tue, 04.05.2021
Newron Pharmaceuticals S.p.A.
Newron announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA
Milan, Italy - May 4, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it re [ … ]
Tue, 13.04.2021
Newron Pharmaceuticals SpA
Milan, Italy - April 13, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that its shareholders approved the sole motion on the agenda of the AGM 2021 held today, being [ … ]
Tue, 13.04.2021
Newron Pharmaceuticals S.p.A.
Newron announces AGM 2021 result
Milan, Italy - April 13, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that its shareholders approved the sole motion on the agenda [ … ]
Thu, 01.04.2021
Newron Pharmaceuticals SpA
Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia
Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021
Milan, Italy and Morristown, NJ, USA, April 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: [ … ]
Thu, 01.04.2021
Newron Pharmaceuticals S.p.A.
Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia
Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia
Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to sta [ … ]
Thu, 21.01.2021
Newron Pharmaceuticals S.p.A.
Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients
Final study data intended to support the initiation of Newron's planned phase III pivotal trial program for evenamide
Milan, Italy and Morristown, NJ, USA, January 21, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETR [ … ]
Tue, 15.09.2020
Newron Pharmaceuticals S.p.A.
Newron announces half-year 2020 results
Milan, Italy, September 15, 2020 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational progres [ … ]
Tue, 11.08.2020
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals provides clinical and business update
All evenamide pre-clinical studies requested by FDA completed and first clinical safety study initiated; on track to initiate evenamide Phase III program in 2021
In advanced evaluation of opportunities to broaden pipeline of treatments for central and peripheral nervous system diseases
[ … ]